Type 2 pRCC and ccRCC were more active than chRCC in RCC classical pathways, such as EGFR and VEGFR pathways, whilst chRCC was more active in MTOR pathway (Figure 7E). This evidence concerns the gene EGFR and nonpapillary renal cell carcinoma.